Skip to main content
. Author manuscript; available in PMC: 2012 Jul 11.
Published in final edited form as: Am J Clin Oncol. 2009 Oct;32(5):453–459. doi: 10.1097/COC.0b013e3181925176

TABLE 1.

Patient Characteristics

Gemcitabine + Capecitabine
No. Eligible Patients 40
Median patient age (range) 61.3 yrs (36.0, 80.3)
No. Sex (%)
Male 32 (80)
Female 8 (20)
No. Race (%)
White 36 (90)
African-American 3 (7)
Native American 1 (3)
No. Hispanic Origin (%)
Yes 1 (3)
No 34 (85)
Unknown 5 (12)
No. Performance Status (%)
0 17 (42)
1 21 (53)
2 2 (5)
No. Prior Therapy (%)
Immunotherapy 22 (55)
Nephrectomy 30 (75)
Radiotherapy 3 (7)
No. Tumor Histology (%)
Clear Cell 33 (82)
Papillary 2 (5)
Adenocarcinoma 1 (3)
Other (e.g. sarcomatoid) 3 (7)
Unknown 1 (3)
No. of Metastatic Sites (%)
1 6 (15)
2 12 (30)
≥3 22 (55)